Log in

ITUS Stock Forecast, Price & News

+0.21 (+8.86 %)
(As of 09/19/2020 12:07 AM ET)
Today's Range
Now: $2.58
50-Day Range
MA: $2.36
52-Week Range
Now: $2.58
Volume475,100 shs
Average Volume247,885 shs
Market Capitalization$61.38 million
P/E RatioN/A
Dividend YieldN/A
Anixa Biosciences, Inc. engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body's immunological response to the presence of a malignancy. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.76 out of 5 stars

Industry, Sector and Symbol

Industry Computer Peripherals
Phone(408) 708-9808



Sales & Book Value

Annual SalesN/A



Market Cap$61.38 million
Next Earnings Date1/14/2021 (Estimated)
OptionableNot Optionable
+0.21 (+8.86 %)
(As of 09/19/2020 12:07 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANIX News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ITUS (NYSE:ANIX) Frequently Asked Questions

How has ITUS's stock been impacted by Coronavirus (COVID-19)?

ITUS's stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ANIX stock has increased by 24.6% and is now trading at $2.58.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of ITUS?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ITUS in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ITUS

When is ITUS's next earnings date?

ITUS is scheduled to release its next quarterly earnings announcement on Thursday, January 14th 2021.
View our earnings forecast for ITUS

How were ITUS's earnings last quarter?

ITUS Corporation (NYSE:ANIX) released its quarterly earnings results on Monday, March, 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.13).
View ITUS's earnings history

What price target have analysts set for ANIX?

2 equities research analysts have issued twelve-month target prices for ITUS's stock. Their forecasts range from $8.00 to $8.50. On average, they expect ITUS's share price to reach $8.25 in the next year. This suggests a possible upside of 219.8% from the stock's current price.
View analysts' price targets for ITUS

Who are some of ITUS's key competitors?

What other stocks do shareholders of ITUS own?

Who are ITUS's key executives?

ITUS's management team includes the following people:
  • Amit Kumar, Executive Chairman, President & CEO
  • Michael J. Catelani, Chief Operating & Financial Officer
  • John A. Roop, Senior Vice President-Engineering
  • Anthony Campisi, Vice President-Engineering

What is ITUS's stock symbol?

ITUS trades on the New York Stock Exchange (NYSE) under the ticker symbol "ANIX."

How do I buy shares of ITUS?

Shares of ANIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ITUS's stock price today?

One share of ANIX stock can currently be purchased for approximately $2.58.

How big of a company is ITUS?

ITUS has a market capitalization of $61.38 million.

How can I contact ITUS?

The company can be reached via phone at (408) 708-9808.

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.